Exelixis | EXEL - Ebitda


Exelixis reported $258.29M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bayer EUR 4.45B 2.49B Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Eisai JPY -335M 30.43B Mar/2026
Eli Lilly USD 12.14B 4.26B Dec/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Exelixis USD 258.29M 15.43M Mar/2026
Genmab DKK 186M 291M Dec/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Merck USD 6.3B 2.09B Dec/2025
Moderna USD -790M 582M Dec/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 5.66B 3.77B Sep/2025
Takeda JPY 150.25B 297.88B Mar/2026
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Xencor USD -51.05M 55.28M Dec/2025